YouTube video by 11Alive

YouTube video by Folk ABC - Americana, Blues, Country

YouTube video by Max13460

YouTube video by Max13460

YouTube video by Fabricando

YouTube video by Release - Topic

Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with hundreds of subscribers.

YouTube video by JCO Media Network

Click to view the official SEC document.

Rein Therapeutics (RNTX) will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, on September 8, 2026.The poster, titled “Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study”, will be presented in the session “Immunological mechanisms in pulmonary fibrosis” (Poster PA6217) from 12:30–2:00pm CEST by Philip Molyneaux, MD. The company notes that the data have been published in Nature Communications.

The presentations are scheduled for Sept. 11 and 14 in New York, with live webcasts and archived replays available for about 90 days.

Click to view the official SEC document.

Phase 2 RENEW trial underway; interim data expected in H2 2026.

Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. FDA has granted Fast Track designation to its lead candidate LTI-03 for treating idiopathic pulmonary fibrosis (IPF). Fast Track is intended to speed development and review of therapies for serious conditions with unmet medical needs and can allow more frequent FDA interaction, rolling submissions, and potential consideration for Accelerated Approval and Priority Review.LTI-03, previously granted Orphan Drug designation for IPF, is a first-in-class inhaled peptide designed to inhibit lung scarring while preserving alveolar progenitor cells, aiming to slow fibrosis and support lung repair. The ongoing RENEW Phase 2 randomized, placebo-controlled trial plans to enroll about 120 IPF patients across the U.S., U.K., Australia, Poland, and Germany, with safety through Week 24 as the primary endpoint and change in forced vital capacity as the primary efficacy endpoint. According to Rein Therapeutics, interim data are expected in the second half of 2026.

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17, Zacks reports. Rein Therapeutics Stock Performance Shares of RNTX stock traded up $0.02 on Friday, hitting $0.81. The company had a trading volume of 211,019 [...]

Rein Therapeutics (NASDAQ:RNTX) reported second quarter 2026 results and a business update, highlighting progress of its global Phase 2 RENEW trial of inhaled LTI-03 in idiopathic pulmonary fibrosis (IPF). The company has surpassed 25% of planned enrollment (≈120 patients) across the U.S., U.K., Australia, Germany and Poland, with enrollment tracking ahead of schedule and interim data expected in the second half of 2026.Rein completed an oversubscribed $57.5 million underwritten public offering, which, together with existing cash, is expected to fund operations and fully finance the RENEW trial into the first quarter of 2028. A peer-reviewed first-in-human LTI-03 study showing reductions in markers of lung scarring was published in Nature Communications in July 2026.As of June 30, 2026, cash, cash equivalents and marketable securities were $43.6 million. Second quarter R&D expense was $3.6 million (down from $4.3 million a year earlier), G&A was $2.4 million (vs. $2.6 million), and net loss was $6.4 million (vs. $6.8 million).

Rein Therapeutics (NASDAQ:RNTX) reported that first-in-human clinical data for its inhaled IPF candidate LTI-03 have been published in peer-reviewed journal Nature Communications. The randomized, placebo-controlled dose-escalation study enrolled 24 idiopathic pulmonary fibrosis patients treated with 5 or 10 mg/day LTI-03 or placebo for 14 days.According to Rein Therapeutics, LTI-03 was well-tolerated at both doses, with only mild or moderate side effects and no treatment-related discontinuations, and showed no systemic absorption. Samples from deep lung regions showed statistically significant reductions in multiple biomarkers of fibrosis and inflammation, including IL-11 and TSLP at both doses, and COL1A1, CXCL7, galectin-7, plus a trend toward reduced SP-D at the higher dose. The company said these results support the scientific rationale and design of its ongoing RENEW Phase 2 trial, which aims to enroll about 120 IPF patients to assess safety, tolerability, and lung function (FVC change).